Depot, Pellet, Matrix, Or Suppository Patents (Class 424/433)
  • Patent number: 10383891
    Abstract: The present invention relates to a composition for intravaginal and/or for internal mucosal application, comprising an effective amount of a sulfated polysaccharide, one or more of a natural quaternary polymer, a quaternary molecular compound, a metalloproteinase inhibitor, one or more anti-inflammatory agent, an acid pH control buffering system or any combination thereof, and a pharmaceutically acceptable carrier. The invention is further related to a method of treating or alleviating vaginal infection, vaginal dryness, vaginal or vulvo vaginal atrophy, vaginal itching, dyspareunia, vaginal or vulvar pain, vaginal or perivaginal inflammation or for promoting vaginal or wound healing, vaginal atrophy/dryness caused by radiotherapy, chemotherapy and/or hormonal treatment and decreased vaginal boundary lubrication or a disease or condition associated therewith or of improving vaginal boundary lubrication.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: August 20, 2019
    Assignee: ALGAMED THERAPEUTICS (A.M.T) LTD.
    Inventor: Ronnie Klein
  • Patent number: 10092715
    Abstract: Disclosed is a method for oral administration of a liquid containing an active substance to a subject for improved absorption into the subject's bloodstream. It includes the steps of providing a delivery device containing the liquid and having a mouthpiece for directing the liquid in a defined direction during delivery; directing the mouthpiece toward a localized area of the subject's mouth being especially suitable for relatively increased uptake and relatively faster onset of action of the active substance; and delivering a measured amount of the liquid directly to the area using the device. Also disclosed is a spray device that includes a container capable of holding a liquid containing an active substance, and a mouthpiece constructed to dispense the liquid in a defined direction and directly to a localized area of a subject's mouth, the localized area being the oral vestibule.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: October 9, 2018
    Assignee: Niconovum USA, Inc.
    Inventors: Anders Axelsson, Karl Olov Fagerström
  • Patent number: 10092615
    Abstract: The present invention relates to a fertility-enhancing composition for human male fertility therapy and a method for using the same to improve or enhance human male fertility. The nutritional supplement composition of the invention includes an effective amount of L-carnitine, coenzyme Q10, vitamin B12, N-acetyl L-cysteine, and grape seed extract.
    Type: Grant
    Filed: April 30, 2016
    Date of Patent: October 9, 2018
    Assignee: Fairhaven Health, LLC
    Inventor: Suzanne Munson
  • Patent number: 9675546
    Abstract: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: June 13, 2017
    Inventors: Bernadette Klamerus, Janet A. Chollet, Fred Mermelstein
  • Patent number: 9597287
    Abstract: An edible oral film strip dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: March 21, 2017
    Assignee: LTS Lohmann Therapic-Systeme AG
    Inventors: Michael Hsin Chwen Li, Markus Krumme
  • Patent number: 9545391
    Abstract: This invention relates to an externally applied ointment that aids in relieving irritation, pain or mild inflammation of the skin or mucous membranes associated with hemorrhoids and the method of using such ointment lotion. The formulation of the present invention contains phenylephrine HCl, lidocaine grape skin/seed/leaf extract and aloe plants extract.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: January 17, 2017
    Assignee: Hemaway LLC
    Inventors: Archer Rosenblum, John Maurello
  • Patent number: 9480662
    Abstract: The present invention provides topical compositions and methods for administering tamoxifen citrate while minimizing the incidence and or severity of adverse drug experiences associated with tamoxifen therapy. In one aspect, these compositions and methods provide a lower plasma concentration of tamoxifen metabolites, such as 4-hydroxytamoxifen and N-desmethyltamoxifen, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient tamoxifen as the sole active agent to benefit a subject with tamoxifen therapy.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: November 1, 2016
    Inventors: Janet A. Chollet, Fred H. Mermelstein
  • Patent number: 9420863
    Abstract: The present invention is directed to methods, compositions and kits for neutralizing alkaline hair. The present invention is also directed to methods, compositions and kits for straightening human hair. The methods comprise neutralizing the hair with a hair neutralizing composition comprising at least one fatty acid. The compositions comprise neutralizing compositions comprising at least one fatty acid. The kits comprise an alkali hair relaxer or components for preparing such a relaxer and the hair neutralizing compositions.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: August 23, 2016
    Assignee: SPARTAN BRANDS, INC.
    Inventors: Patrick Obukowho, Gary Grey, Mark Szelast
  • Patent number: 9216106
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: December 22, 2015
    Assignee: DIRECTCONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Patent number: 9023380
    Abstract: The present invention provides a hair graft comprising (a) tissue engineered skin comprising a tissue engineered epidermal layer, a tissue engineered dermal layer, and hair follicle progenitor cells and (b) a scaffold. The invention also provides methods of making and using the hair grafts of the present invention.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Aderans Research Institute, Inc.
    Inventors: Thomas H. Barrows, Preeti MacIntyre, Kenneth Justin Washenik
  • Patent number: 8992968
    Abstract: A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: March 31, 2015
    Assignee: Poly-Med, Inc.
    Inventor: Shalaby W. Shalaby
  • Patent number: 8962010
    Abstract: An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: February 24, 2015
    Assignee: Warner Chilcott Company, LLC
    Inventors: David Aaron Woolfson, Karl Malcolm
  • Patent number: 8900615
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff
  • Patent number: 8871244
    Abstract: The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 28, 2014
    Assignee: Rolf Kullgren AB
    Inventor: Björn Andersch
  • Patent number: 8865201
    Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: October 21, 2014
    Assignee: Polichem SA
    Inventors: Stefano De Luigi Bruschi, Federico Mailland
  • Patent number: 8858977
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff, Henk Jan Out
  • Patent number: 8790685
    Abstract: Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: July 29, 2014
    Assignee: Mipharm S.p.A.
    Inventor: Massimo Prini
  • Publication number: 20140205650
    Abstract: The invention relates to coating of suppositories containing free unsaturated fatty acid, fatty acid ethyl ester and fatty acid monoglyceride that are susceptible to oxidative degradation. The coating retards oxidative degradation of unsaturated fatty acids and gives the suppository a non-oily and smooth surface. The coating will enhance the shelf-life of the suppository and allow their storage at room temperature for extended time period. The coating may or may not contain medicament such as local anesthetic or steroid. According to this invention chemically unstable fatty acids in coated suppositories can be used to stimulate the process of defecation or to treat disorders such as hemorrhoids, bacterial infections, viral infections and inflammations, as well as against fissura ani and pruritus ani. Furthermore, coating suppositories, that contain high concentrations of free fatty acids, can reduce acid induced rectal irritation.
    Type: Application
    Filed: September 6, 2012
    Publication date: July 24, 2014
    Applicant: LIPID PHARMACEUTICALS EHF.
    Inventor: Thorsteinn Loftsson
  • Patent number: 8784872
    Abstract: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: July 22, 2014
    Assignee: Comgenrx, Inc.
    Inventors: Bryan T. Oronsky, Neil C. Oronsky, Arnold L. Oronsky
  • Patent number: 8741330
    Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 3, 2014
    Inventors: Paul Zupkas, C. Lowell Parsons
  • Patent number: 8703171
    Abstract: The present invention relates to a method of easing childbirth using a composition having a lubricant effect for use in particular during human vaginal delivery. The methods comprise applying a bioadhesive composition comprising (a) a polyacrylic acid, (b) a water-soluble thickener and (c) a humectant and (d) optionally water.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: April 22, 2014
    Assignee: HCB Happy Child Birth Holding AG
    Inventor: Andreas F. Schaub
  • Patent number: 8518434
    Abstract: This invention provides a spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients: at least one benzalkonium chloride, in an amount from 0.05 to 0-0.2%; at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in an amount of from 0.05-4%, and triclosan in an amount from 0.05-2%; a biologically acceptable emollient, in an amount from 1-5%; hydroxypropyimethyl cellulose, in an amount from 0.1-3%; sodium carbomer, in an amount from 0.1-1%; de-ionized water, making up the balance. The composition has the attributes of (a) a semi-solid, essentially clear gel consistency and appearance, and (b) the ability to maintain a presence in the human vagina in the presence of mucous secretions therein, in virucidally effective amounts, for at least 24 hours after application thereto.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: August 27, 2013
    Assignee: St. Michael's Medical, Inc.
    Inventors: George M. Livingston, David B. Thornburgh, Jeffrey Longmore
  • Patent number: 8436051
    Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: May 7, 2013
    Assignee: Aptalis Pharma Canada Inc.
    Inventors: Carl Gauthier, Yves Dumoulin, David Powell, Hugues Moreau
  • Patent number: 8420114
    Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: April 16, 2013
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John M. Zanella, Sara Waynick
  • Patent number: 8399013
    Abstract: This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: March 19, 2013
    Assignee: Poly-Med, Inc.
    Inventor: Shalaby W. Shalaby
  • Patent number: 8399012
    Abstract: A biodegradable biodelivery device is disclosed. The biodelivery device is formed from a polymer comprising the reaction product of a polyol and a polyacid. When exposed to water, the polymer degrades through hydrolysis. Of particular advantage, the polymer can be formed so as to be elastic and flexible. In one embodiment, the polymer is formed into a vaginal insert. As the polymer degrades, the polymer releases acid to a vaginal environment for decreasing the pH of the environment.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: March 19, 2013
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Molly K. Smith, Kelly D. Arehart, Lei Huang, Shu-Ping Yang, Yanbin Huang
  • Patent number: 8388996
    Abstract: A method is provided for manufacturing a medicated tampon assembly having a tampon body, the method including applying a formulation including a therapeutic agent to a substrate to produce a plurality of dosage forms; separating one of the dosage forms from the substrate; and coupling one of the dosage forms to the tampon body. A medicated tampon assembly is provided including a dosage form including a formulation including a therapeutic agent; a substrate portion separated from a substrate, wherein the substrate portion is coupled to the dosage form; and a tampon body having a distal end, wherein the substrate portion is coupled to the distal end of the tampon body.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: March 5, 2013
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Steven C. Gehling, Gregory J. Rajala, James D. Milner, Dennis S. Everhart
  • Patent number: 8367098
    Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified antiretroviral agents comprising NNRTIs and NRTIs. Also disclosed are methods for making and using the compositions.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: February 5, 2013
    Assignee: The Population Council, Inc.
    Inventors: Mitchell Thorn, Naomi Rutenberg
  • Patent number: 8333983
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: December 18, 2012
    Assignee: MSD Oss B.V.
    Inventors: Rudolf Johannes Joseph Groenewegen, Wouter De Graaff, Henk Jan Out
  • Patent number: 8282954
    Abstract: The present invention provides a process for making an edible film having a substantially uniform distribution of components, which includes the steps of combining a water-based film polymer solution and a slurry-type mixture comprising a water-active component and a solvent; mixing the polymer solution and slurry-type mixture for about 10 minutes or less; dispensing the mixed solution and slurry-type mixture to form a film; and drying the film to evaporate the water and solvent. Films made by the process are also provided.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: October 9, 2012
    Assignee: MonoSol Rx, LLC
    Inventors: Beuford A. Bogue, Garry L. Myers
  • Patent number: 8268343
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: September 18, 2012
    Inventors: Brij Saxena, Mukul Singh, Sidney Lerner
  • Patent number: 8263111
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: September 11, 2012
    Inventors: Brij Saxena, Mukul Singh, Sidney Lerner
  • Patent number: 8258164
    Abstract: An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl carboxylic acid (e.g., acetic acid), a polybasic acid (e.g., citric acid, tartaric acid, malic acid, polyacrylic acid, and the like), or a combination thereof. The composition can further include a thickening agent, to form a gel. The composition is free from organic co-solvents, water-soluble vitamins, and cyclodextrins; and free from nitroimidazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: September 4, 2012
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 8226972
    Abstract: Drug delivery compositions which are suitable for vaginal administration for the treatment of diseases and disorders in the urogenital tract are described. The compositions may be in the form of a tablet, liquid suspension or dispersion, dried powder, topical ointment, cream, foam, suppository, or aerosol. The drug delivery compositions are administered directly to the vagina and do not require the use of a solid device. This method of administration reduces the systematic levels of the drugs.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: July 24, 2012
    Assignee: FemmePharma Holding Company, Inc.
    Inventors: Gerianne Tringali DiPiano, John A. Ziemniak, Thomas Janicki
  • Patent number: 8217083
    Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: July 10, 2012
    Assignee: Aptalis Pharma Canada Inc.
    Inventors: Carl Gauthier, Yves Dumoulin, David Powell
  • Patent number: 8217219
    Abstract: A vaginal insert formed from a composition that, prior to introduction to the vagina, has the physical properties of a liquid, semi-soft gel, paste, foam, or viscous material so that it can be effectively delivered to the vaginal canal. After introduction into the vagina, the composition will expand and/or solidify into a semi-solid or solid structure to substantially fill the entire “H” shaped space of the vagina and a portion of the rugal folds along the length of the vaginal canal. Upon solidifying, the composition defines an insert that, in one embodiment, is suitable for use as a tampon and, in another embodiment, is suitable for use as an incontinence device.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: July 10, 2012
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Kristin M. Shepard, MaryAnn Zunker
  • Patent number: 8196745
    Abstract: A suppository delivery device that allows for the insertion of a suppository without having contact with the suppository or rectum. The suppository delivery device includes a stabilizing platform, a stabilizer to which the suppository is mounted, and a package, which protects the user's hands and fingers from the suppository and rectum and prevents germs from contacting the suppository before being inserted into the rectum.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: June 12, 2012
    Assignee: Just Like Sisters, LLC
    Inventors: Karen D. Higgins, Kathleen K. Pieper
  • Publication number: 20120107385
    Abstract: The present invention is directed to a method of treating a condition associated with an overactive bladder, comprising administering to a female an intravaginal device, comprising: (a) an annular first matrix comprising a pocket and a pocket wall, wherein the pocket wall has a uniform thickness, and wherein the pocket wall encompasses the pocket; and (b) a second matrix comprising an anticholinergic agent located in the pocket.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 3, 2012
    Inventors: Anu Mahashabde, Jiaxiang Tsao
  • Publication number: 20120093911
    Abstract: The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for the cross-linking reaction. The vaginal rings surprisingly achieve relatively high and steady release rates in vivo with a matrix ring containing a relatively small loading dose. While the matrix rings of the present invention have in vivo the steady release rates associated with reservoir rings, they are easier and less expensive to manufacture. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, and methods of preparing platinum-catalyzed intravaginal rings.
    Type: Application
    Filed: October 19, 2011
    Publication date: April 19, 2012
    Applicant: International Partnership for Microbicides
    Inventors: Karl Malcolm, David Woolfson, Joseph Romano
  • Patent number: 8138265
    Abstract: A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: March 20, 2012
    Assignee: The Cleveland Clinic Foundation
    Inventors: Anthony Calabro, Aniq B. Darr, Richard A. Gross
  • Patent number: 8137706
    Abstract: Carbohydrates, in particular mannose containing carbohydrates, are used as a promotor of cell growth. Specifically, polysaccharide hydrolysates are shown to have superior efficacy in promoting the growth of cells, synbiotic foods, prebiotics and pharmaceutical compositions containing mannose containing carbohydrates and polysaccharide hydrolysates described.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: March 20, 2012
    Assignee: Glycologic Limited
    Inventors: Farage Al-Ghazzewi, Richard Tester
  • Patent number: 8105622
    Abstract: Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 31, 2012
    Assignee: Incept LLC
    Inventor: Amarpreet S. Sawhney
  • Patent number: 8062658
    Abstract: Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: November 22, 2011
    Assignee: Poly-Med, Inc.
    Inventors: Shalaby W Shalaby, Georgios T Hilas
  • Patent number: 8057817
    Abstract: This invention generally covers a ringed-mesh intravaginal device and applicator therefore wherein the ringed-mesh comprises a composite ring comprising a flexible matrix containing one or more bioactive agent or agents and needed excipients or modulators, and the said matrix is reinforced with a fibrous construct to provided needed initial and in-use biomechanical stability. Of special application of the medicated, ringed-mesh is its use for securing contraception relying on biomechanical, pharmacological, and biochemical means.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: November 15, 2011
    Assignee: Poly-Med, Inc.
    Inventor: Shalaby W Shalaby
  • Patent number: 8021350
    Abstract: A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: September 20, 2011
    Assignee: The Cleveland Clinic Foundation
    Inventors: Anthony Calabro, Aniq B. Darr, Kiyotaka Fukamachi, Richard A. Gross, Keiji Kamohara, Michael K. Banbury
  • Patent number: 7993667
    Abstract: A method is provided for manufacturing a medicated tampon assembly having a tampon body, the method including applying a formulation including a therapeutic agent to a substrate to produce a plurality of dosage forms; separating one of the dosage forms from the substrate; and coupling one of the dosage forms to the tampon body. A medicated tampon assembly is provided including a dosage form including a formulation including a therapeutic agent; a substrate portion separated from a substrate, wherein the substrate portion is coupled to the dosage form; and a tampon body having a distal end, wherein the substrate portion is coupled to the distal end of the tampon body.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: August 9, 2011
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Steven C. Gehling, Gregory J. Rajala, James D. Milner, Dennis S. Everhart
  • Patent number: 7863335
    Abstract: Methods for treating or reducing the risk of transmission of chlamydia to a recipient by topically applying a metalloprotease inhibitor to a site on the recipient which is likely to be exposed to Chlamydia. Topical compositions containing metalloprotease inhibitors are also disclosed for treating or reducing the risk of transmission of Chlamydia, as well as barrier contraceptive devices coated therewith.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: January 4, 2011
    Assignee: The University of Medicine and Dentistry of New Jersey
    Inventor: Huizhou Fan
  • Publication number: 20100330138
    Abstract: Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer.
    Type: Application
    Filed: May 11, 2009
    Publication date: December 30, 2010
    Inventors: Shalaby W. Shalaby, Georgios T. Hilas
  • Patent number: 7815929
    Abstract: A container suitable for the preparation, storage and dispensing of compounded suppositories is provided. Methods of preparing, storing and dispensing compounded suppositories utilizing such a container and related kits are also provided.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: October 19, 2010
    Assignee: CutisPharma, Inc.
    Inventors: Indu Muni, Gita Muni, Dilip Patel, Peter Mione, Denis Morin
  • Patent number: 7777609
    Abstract: A radio-frequency tag communication device arranged to transmit a transmitted signal toward a radio-frequency tag and to receive a reply signal transmitted from the radio-frequency tag in response to the transmitted signal, for thereby effecting radio communication with the radio-frequency tag, the radio-frequency tag communication device including (a) a receiver portion including a receiver antenna device which has a plurality of receiver antenna elements for receiving the reply signal from the radio-frequency tag, (b) a reception-directivity control portion which controls the directivity of reception of the receiver portion device, by controlling the phase of a received signal which is received by each of the plurality of receiver antenna elements and which may include a leakage signal which is a part of the transmitted signal, (c) a modulated-component extracting portion which extracts a modulated component of the received signal which is modulated by the radio-frequency tag, and (d) a direction detecting
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 17, 2010
    Assignee: Brother Kogyo Kabushiki Kaisha
    Inventor: Katsuyuki Kuramoto